Virtual patients could revolutionize cancer drug testing

NCT ID NCT07757022

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial is testing whether artificial intelligence can create 'digital twin' models of esophageal cancer patients to predict how they will respond to a combination of immunotherapy and chemotherapy. The study will compare the AI's predictions against real outcomes in patients receiving the treatment. The goal is to see if virtual clinical trials can help personalize treatment and speed up drug development.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A combination of toripalimab (an immunotherapy drug), paclitaxel (chemotherapy), and cisplatin (chemotherapy), given before and after surgery.
What this could lead to
If successful, this could pave the way for using AI digital twins to predict which drug combinations work best for individual esophageal cancer patients, potentially speeding up treatment discovery and personalizing care.
What could go wrong
This is an early-stage approach, and the AI predictions may not match real-world outcomes. The trial is also limited to a specific type of esophageal cancer, so results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.